Bayer Shares Under Pressure Following Disappointing Earnings

Bayer shares fall sharply after disappointing Q4 2025 results and a cut to profit forecasts. The stock is down 21% in a month, trading at oversold levels.

Investor sentiment toward the pharmaceutical and agricultural giant Bayer has soured, with its stock performance lagging behind broader market gains. The downturn is primarily driven by weak fourth-quarter 2025 results and a downward revision in profit forecasts, creating a noticeable sell-off.

Earnings Miss Drives Sell-Off

The company's recent financial update revealed a significant year-over-year decline. For Q4 2025, Bayer's adjusted earnings per share contracted to 0.62 euros, a sharp fall from the 1.05 euros reported for the same period last year. Revenue also softened, decreasing by approximately 2.5% to 11.44 billion euros. Market analysts are growing increasingly cautious, pointing to a persistent negative trend in profit guidance that has been solidifying since early February.

Technical Picture Reflects Fundamental Weakness

This fundamental disappointment is clearly illustrated in the stock's chart performance. The equity has shed roughly 21% of its value over the last 30 trading days alone. Closing yesterday at 38.84 euros, the share price has moved substantially lower from its 52-week high of 49.17 euros, which was reached in mid-February. While a Relative Strength Index (RSI) reading of 20.9 suggests the stock is deeply oversold, this technical indicator alone does not guarantee a near-term rebound. The price continues to trade below its key moving averages, indicating sustained bearish pressure.

Outlook and Upcoming Catalysts

Current consensus estimates among market experts project earnings per share of 4.37 euros for the full 2026 fiscal year, alongside a dividend of 0.109 euros. The next major opportunity for the company to shift the narrative will come with the release of its Q1 2026 financial statement on May 12, 2026. In the interim, the stock's trajectory is likely to be influenced by broader macroeconomic sentiment within the chemical sector and developments in global agricultural markets.